| Biomarker ID | 161 |
| PMID | 16618727 |
| Year | 2006 |
| Biomarker | MYO6 (Myosin VI) [MYO6-0041] |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Gap junction degradation,Gap junction trafficking and regulation,Glutamate binding and activation of AMPA receptors and synaptic plasticity, Membrane trafficking,Transmission across chemical synapses |
| Experiment | Cancerous Tissue Vs Normal Tissue |
| Type of Biomarker | Diagnostic |
| Cohort | Two sets of Patients were included in the study. Set 1 included 10 cancerous, and 6 normal tissues. Set 2 included 12 cancerous and 10 normal tissues |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | 1.15E-08 |
| Method Used | RT-PCR and qPCR |
| Clinical | No |
| Remarks | Brackets indicate ISOFORMS of the mRNA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MYO6 |